AbbVie Inc. $ABBV Stock Position Decreased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 32.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,906 shares of the company’s stock after selling 5,131 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in AbbVie were worth $2,525,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter worth $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the second quarter worth about $36,000. Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the 2nd quarter worth about $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in AbbVie in the 3rd quarter valued at about $41,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $1.73 per share (annualized yield ~3.1%), payable May 15 to holders of record April 15 — supports income investor demand and underscores management’s commitment to returning cash. AbbVie Declares Quarterly Dividend
• Positive Sentiment: Investment write-ups highlight AbbVie as a Dividend King and a multi-area biotech with durable cash flows — narrative that attracts dividend-focused buyers. 2 Dividend Stocks to Hold for the Next 5 Years
• Positive Sentiment: VOLITE skin-quality trial reported completion updates — clinical progress in aesthetics could help diversify revenue beyond core immunology franchises. AbbVie’s VOLITE Skin Quality Trial Completion
• Positive Sentiment: Coverage pieces suggest AbbVie’s post-Humira pipeline progress (Tremfya and others) could prompt renewed investor interest if share gains and new launches continue. This is a potential catalyst for medium-term revenue growth. Should AbbVie’s Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: AbbVie launched a branded podcast, “The Persistence Lab,” to highlight innovation — helpful for PR/brand but unlikely to move fundamentals quickly. AbbVie heads to ‘The Persistence Lab’
• Neutral Sentiment: Analyst commentary and aggregator pieces (Zacks, Yahoo Top Analyst Reports) continue to highlight AbbVie following its earnings beat — supportive background but mixed across firms. The Zacks Analyst Blog
• Negative Sentiment: Evercore trimmed its price target slightly and warned that while Tremfya is gaining share, future earnings growth could be limited — a caution that may restrain upgrades and cap near-term upside. Evercore Notes Tremfya Gains Market Share

AbbVie Price Performance

Shares of ABBV opened at $224.13 on Friday. The firm’s 50 day moving average is $224.01 and its 200-day moving average is $221.70. The stock has a market capitalization of $396.12 billion, a P/E ratio of 94.97, a P/E/G ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the business posted $2.16 EPS. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is currently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research report on Thursday, January 15th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Barclays assumed coverage on AbbVie in a report on Thursday. They set an “overweight” rating and a $275.00 price target on the stock. Finally, Evercore reduced their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $252.79.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.